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832A Prospective Study of Iron Overload Management
in Allogeneic Hematopoietic Cell Transplantation
Survivors
Navneet S. Majhail,1 Hillard M. Lazarus,2 Linda J. Burns1We report the results of a single-center, prospective evaluation for iron overload and subsequent treatment
in 147 adult allogeneic hematopoietic cell transplantation (HCT) recipients who survived beyond 1 year after
transplantation. Patients were screened by serum ferritin level; those with ferritin.1000 ng/mL underwent
liver R2 magnetic resonance imaging to estimate liver iron concentration (LIC; normal #1.8 mg/g). Patients
with significant iron overload (defined as LIC$5 mg/g), based on physician and patient preference, were of-
fered observation only, phlebotomy, or enrollment in a pilot study of deferasirox. Sixteen patients had sig-
nificant iron overload. Their median age was 51 years (range, 29-64 years), and they had survived
a median of 21 months (range, 12-114 months). All 16 patients were transfusion-independent at study en-
rollment. Five patients received no treatment (median LIC, 6.4 mg/g; range, 5.1-28.3 mg/g), 8 underwent
phlebotomy (median LIC, 13.1 mg/g; range, 7.8-43.0 mg/g), and 3 received daily deferasirox 20 mg/kg/day
orally for 6months (LIC, 6.3, 9.0, and 19.9 mg/g). Two patients had abnormal liver function tests, and 1 patient
each had cirrhosis and unexplained congestive heart failure; all 4 of these patients underwent phlebotomy.
Follow-up serum ferritin concentrations decreased spontaneously in 4 patients in the observation-only
arm. Phlebotomy was generally well tolerated. Deferasirox also was well tolerated and led to decreased
LIC after 6 months of therapy in all 3 patients. Phlebotomy is feasible in the majority of allogeneic HCTre-
cipients who have survived for$1 year after HCTand have significant iron overload. Although the number of
subjects is small, deferasirox may be a safe and effective alternative for allogeneic HCT survivors with iron
overload who cannot undergo phlebotomy.
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Transfusion-related iron overload occurs in 30%-
60% of allogeneic hematopoietic cell transplantation
(HCT) recipients [1-3]. Post-HCT iron overload has
been associated with such early complications as
infections and hepatic sinusoidal obstruction
syndrome [2,4,5]. Iron overload increases the risk of
hepatic fibrosis and cardiomyopathy in long-term1Blood and Marrow Transplant Program, University
innesota, Minneapolis, Minnesota; and 2Division of
tology and Oncology, Case Western Reserve University,
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who become transfusion- independent after HCT
but continue to have a high body iron burden [6,7].
The natural history of iron overload and its impact
on late organ dysfunction in adult long-term HCT
survivors remain unclear. Based on experience in
children with hemoglobinopathies, adult allogeneic
HCT survivors with persistently elevated body iron
levels may be at risk for developing hepatic and
cardiac dysfunction.
The management of posttransplantation iron
overload in adult HCT survivors has not been well
studied. Although long-term follow-up guidelines rec-
ommend screening with serum ferritin measurements
at 1 year post-HCT [8], there are no clear-cut criteria
for when and how to treat iron overload. Treatment
options include phlebotomy and iron chelation ther-
apy. Phlebotomy can be considered the treatment of
choice because of its safety and efficacy, but it may
not be feasible in patients with coexisting anemia. De-
feroxamine is also feasible, relatively safe, and effica-
cious for treating post-HCT iron overload, but it is
Biol Blood Marrow Transplant 16:832-837, 2010 833Iron Overload in HCT Survivorsinconvenient to administer [2].Deferasirox is a recently
introduced oral iron chelator with efficacy similar to
deferoxamine [9,10]; its safety profile in HCT
recipients has not been established, however. To
determine the optimal management of iron overload
after transplantation, we prospectively evaluated the
management of iron overload in allogeneic HCT
recipients who had survived for 1 year or more after
transplantation.Figure 1. Treatment schema. Assignment to observation or treatment
was determined by physician and patient preference. Patients in the
treatment arm could enroll in a pilot study of deferasirox if they could
not undergo phlebotomy because of anemia (hemoglobin \11 g/dL)
or they refused phlebotomy.METHODS
Patients
Adult allogeneic HCT recipients (aged$18 years)
who had survived$1 year after HCT at the University
of Minnesota Blood and Marrow Transplant Program
were prospectively evaluated for iron overload
(Figure 1). Patients were evaluated primarily for a pilot
study to assess the feasibility and safety of deferasirox
in this population. Patients were initially screened
with serum ferritin measurements; those with serum
ferritin level .1000 ng/mL underwent R2 magnetic
resonance imaging (MRI) of the liver to estimate liver
iron concentration (LIC; normal range, 0.17-1.8 mg/g
dry tissue) [11-13]. Patients with significant iron
overload, defined as LIC $5 mg/g on liver R2 MRI,
were assigned to the observation arm or the
treatment arm based on physician and patient
preference. Among patients assigned to the treatment
arm, phlebotomy was the treatment of choice;
patients who could not undergo phlebotomy because
of anemia (hemoglobin \11 g/dL) or refused
phlebotomy were given the option to enroll in a pilot
study to evaluate the feasibility of deferasirox in
HCT survivors.
The study protocol was approved by the Institu-
tional Review Board, and all participants provided in-
formed consent before enrollment. The deferasirox
pilot study was registered at www.clinicaltrials.gov
(NCT00602446).
Adult recipients of both myeloablative and non-
myeloablative conditioning regimens were eligible.
Patients with any contraindication for MRI and those
with relapse or progression of underlying disease were
excluded. Additional eligibility criteria for patients
considered for the deferasirox pilot study included:
(1) Eastern Cooperative Oncology Group perfor-
mance status of 0-2 and life expectancy $6 months,
(2) adequate renal function (serum creatinine # 1.6
mg/dL and creatinine clearance of $ 60 mL/min on
2 occasions within 30 days of enrollment), (3) adequate
hematopoietic reserve (absolute neutrophil count
$1.0  109/L, hemoglobin $8.0 g/dL, and platelet
count$50 109/L), (4) adequate hepatic function (se-
rum aspartate aminotransferase [AST] and alanine
aminotransferase [ALT]\5 times the upper limit ofnormal), (5) absence of active infection or uncontrolled
graft-versus-host disease (GVHD), (6) not pregnant or
breast feeding and able to use contraception, and (7)
absence of deferasirox therapy within 12 months of
study enrollment.
A total of 147 patients were screened for this study
between January 2008 and August 2009 (Figure 2).
This number included 56 patients who had been en-
rolled in an earlier study evaluating the prevalence of
iron overload in adult allogeneic HCT survivors [1].
Of the 147 patients, 124 were screen failures; these in-
cluded patients with a serum ferritin concentration of
#1000 ng/mL and patients in whom serum ferritin
level was not measured because of patient or transplant
physician refusal for study participation. In addition,
patients who had received\10 red blood cell (RBC)
transfusions since the diagnosis of their hematologic
disorder were not asked to participate in this study.
Twenty-three patients had a serum ferritin concentra-
tion .1000 ng/mL and all of these patients had iron
overload (LIC .1.8 mg/g on liver R2 MRI), 16 with
significant iron overload (LIC $5 mg/g).
Study Evaluations
MRI measurement of LIC was based on the imag-
ing of proton transverse relaxation rates (R2) within
the liver using a 1.5-T MRI machine (MAGNETOM
Avanto; Siemens, Malvern, PA). This noninvasive R2
MRI technique (FerriScan; Resonance Health, Perth,
Australia) has proven highly sensitive and specific for
estimatingLIC in studies comparing itwith liver biopsy
and biomagnetic liver susceptometry using a supercon-
ducting quantum interference device [11-13].
After baseline ferritin measurement and liver MRI,
patients in the observation and phlebotomy arms
underwent follow-up evaluation at the discretion of
their transplant physician. Patients enrolled in the
Figure 2. Patient selection. LICmeasured by liver R2MRI scan (normal
LIC,\1.8 mg/g).
834 Biol Blood Marrow Transplant 16:832-837, 2010N. S. Majhail et al.deferasirox pilot study were evaluated with complete
blood count; serum ALT, AST, and creatinine; urine
protein estimation; and an eye examination at baseline.
They subsequently underwent history and physical ex-
amination; complete blood count; serum AST, ALT,
creatinine, and ferritin; urine protein analysis; and tox-
icity assessment at least monthly for 6 months. At each
monthly visit, all unused drug was collected and
audited to ascertain patient compliance. At the end
of the study, patients also underwent a repeat R2
MRI of the liver for LIC estimation.
Study Treatments
The duration and frequency of phlebotomy were
determined by the transplant physicians. Guidelines
for phlebotomy recommended removal of 1 unit (500
mL) of blood every 2-4weeks until serum ferritin levels
returned to the normal range (\300 ng/mL). Defera-
sirox was administered as a once-daily oral dose of 20
mg/kg for a period of 6 months. Dose adjustments
were allowed for significant changes in weight and in-
adequate decreases in serum ferritin level. Dose adjust-
ments or interruptions also were allowed for changes in
hemoglobin, platelet count, absolute neutrophil count,
and serum creatinine, AST, andALT, and for skin rash.
Statistical Analysis
This deferasirox pilot study was designed to evalu-
ate the feasibility of using deferasirox in adult allogeneic
HCT survivors, as assessed by the proportion of pa-
tients dropping out because of drug-related toxicity
over the course of treatment. The enrollment goal was10 patients, but the study was discontinued after enroll-
ment of 4 patients because of slow accrual. The results
described in this report are primarily descriptive.RESULTS
Patients
Table 1 summarizes transplantation characteristics
and reports baseline serum ferritin and LIC for the 16
patients with significant iron overload in our cohort.
All 16 patients were transfusion-independent at the
time of study enrollment. Their median age was 51
years (range, 29-64 years). They were enrolled at a
median of 22 months (range, 12-155 months) after
transplantation. Their median baseline ferritin con-
centration was 1818 ng/mL (range, 1042-7311 ng/
mL), and their median baseline LIC was 10.1 mg/g
(range, 5.1-43.0 mg/g).
Phlebotomy
Eight patients were considered for phlebotomy
(Table 1). Their median hemoglobin at the onset of
phlebotomy was 13.2 g/dL (range, 12.1-15.5 g/dL).
The patients generally tolerated phlebotomy well,
with a predictable decrease in serum ferritin level,
and did not require frequent interruptions because of
decreased hematocrit concentration. No patient re-
quired the use of an erythrocyte-stimulating agent to
facilitate phlebotomy.
Among the 16 patients with significant iron over-
load, 4 had end-organ damage that could be attributed
to iron overload. All 4 of these patients underwent
phlebotomy. Two patients (LIC, 9.0 and 22.8 mg/g)
had liver function test abnormalities that improved af-
ter a reduction of body iron stores. One patient had
unexplained congestive heart failure (LIC, 15.8 mg/
g). Although cardiac imaging or biopsy to evaluate
iron accumulation in the heart was not done, the pa-
tient’s left ventricular ejection fraction improved
with phlebotomy and initiation and optimization of
cardiac medications. One patient, who also had exten-
sive chronic GVHD (cGVHD), exhibited persistent
liver function test abnormalities despite adequate
control of GVHD manifestations at other sites. The
patient’s serum ferritin concentration at 13 months
post-HCT was 4074 ng/mL, and his LIC on R2
MRI was 43.0 mg/g. Liver biopsy demonstrated cir-
rhosis. On further evaluation, the patient was found
to be homozygous for the C282Y hemochromatosis
gene mutation. He is currently undergoing phlebot-
omy and has improving liver function test results.
Deferasirox
Four patients consented to participate in the defer-
asirox pilot study. One patient withdrew consent
Table 1. Characteristics of Patients with Significant Iron Overload (LIC $5 mg/g on Liver R2 MRI)
Age (years) Sex
Time Since
HCT, Months Diagnosis Conditioning Intensity
Stem Cell
Source
RBC Transfusions
Since Diagnosis Chronic GVHD
Baseline
Ferritin, ng/mL
Baseline
LIC, mg/g
Hepatic or
Cardiac Dysfunction
No treatment
61 M 12 AML NMA UCB 32 Active 1203 5.1 No
36 F 14 CML MA MUD 41 Active 1614 6.4 No
52 F 48 NHL MA MSD 23 Never 1507 7.0 No
51 F 21 AML MA MSD 31 Active 1599 6.4 No
58 M 22 AML NMA MSD 41 Active 7311 28.3 No
Phlebotomy
59 M 115 MDS NMA MUD 18 Resolved 2472 12.6 No
61 M 13 Myelofibrosis NMA MSD 101 Active 4074 43.0 Cirrhosis*
42 M 66 AML MA UCB 24 Resolved 1042 7.8 No
47 F 33 AML MA MSD 27 Never 1508 15.8 Unexplained CHF
64 M 41 AML NMA MSD 44 Active 5147 22.8 Abnormal LFTs
29 M 34 AML MA MSD 39 Active 1283 13.6 No
44 F 14 AML MA MSD 22 Never 1641 11.2 No
53 M 14 NHL MA MSD 26 Active 3502 9.0 Abnormal LFTs
Deferasirox
41 M 15 AML NMA MSD 33 Never 2437 9.0 No
45 M 46 AML MA UCB 32 Resolved 2574 19.9 No
51 M 13 AML NMA MSD 12 Active 1995 6.3 No
AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; NMA, nonmyeloablative; MA, myeloablative; UCB, umbilical cord blood;
MUD, matched unrelated donor; MSD, matched sibling donor; LFT, liver function test; CHF, congestive heart failure.
*This patient was homozygous for the C282Y hemochromatosis gene mutation.
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836 Biol Blood Marrow Transplant 16:832-837, 2010N. S. Majhail et al.before initiation of drug therapy and elected to pursue
phlebotomy instead. Transplantation details and base-
line serum ferritin concentrations and LIC values of
the 3 patients who received deferasirox are given in
Table 1. Baseline hemoglobin values before initiation
of deferasirox were 10.9, 12.3, and 15.5 g/dL in the 3
patients. One patient had limited cGVHD involving
the oral cavity that did not require systemic immuno-
suppression. A second patient had a history of
cGVHD, but had been successfully tapered off all
immunosuppression and had not required systemic
therapy for 9 months before study entry. All 3 patients
demonstrated decreased serum ferritin concentrations
and LIC values after 6 months of deferasirox therapy
(Figure 3).
Deferasirox was well tolerated. One patient experi-
enced a transient decrease in hemoglobin that required
discontinuation of therapy for 2 weeks; the drug was
subsequently restarted at the same dose and continued
without any further interruptions in therapy. This pa-
tient also had a transient mild rash. A second patient
also had a rash, which was considered secondary to
dermatophytosis and not attributed to deferasirox.
All 3 patients had transient diarrhea on initiation of de-
ferasirox therapy that resolved spontaneously without
the need for dose adjustment. Two patients had tran-
sient increases in serum creatinine that were \50%
of their baseline values and did not require dose adjust-
ment. In both patents, serum creatinine values re-
turned to baseline after completion of deferasirox
therapy. Notably, no patient receiving deferasirox
was on concurrent calcineurin inhibitor therapy or
other systemic immunosuppression for GVHD.
Observation
Five patients chose observation only (Table 1).
Reasons for not pursuing treatment for iron overload
included patient or physician preference (n 5 4) and
uncontrolled GVHD (n 5 1). Median hemoglobin at
the time of LIC assessment was 12.4 g/dL (range,Figure 3. Change in serum ferritin concentration over 6 months of
therapy in 3 patients who received deferasirox for treatment of iron
overload. LIC measured by liver R2 MRI at baseline and at completion
of 6 months of therapy is also shown.10.5-14.1 g/dL). Four of these 5 patients were fol-
lowed up with repeat serum ferritin measurements;
all 4 patients demonstrated decreasing concentrations
over time. One patient, who was not anemic at base-
line, underwent a follow-up R2 MRI for LIC assess-
ment. This patient exhibited significant decreases in
both serum ferritin concentration and LIC, from
1599 ng/mL and 6.4 mg/g at baseline to 1019 ng/
mL and 2.6 mg/g at 17-month follow-up.DISCUSSION
The present study highlights some important ob-
servations regarding the treatment of significant trans-
fusion-associated iron overload in adult allogeneic
HCT survivors who have lived for at least 1 year or
more after transplantation: (1) The majority of adult
allogeneic HCT survivors become RBC transfusion–
independent; (2) phlebotomy is well tolerated in
HCT survivors and should be considered the treat-
ment of choice because of its relatively low cost and
minimal risk of side effects; and (3) deferasirox (even
given the small number of patients in our study)
appears to be a well tolerated and effective alternative
for the treatment of significant iron overload in HCT
survivors who cannot undergo phlebotomy.
Phlebotomy was well tolerated in our patient co-
hort. Phlebotomy has been reported to be safe and
effective in the treatment of iron overload in thalasse-
mic children who have undergone allogeneic HCT
[14,15]. Previous case series have reported on the
safety and feasibility of phlebotomy in adult HCT
survivors with iron overload, both with and without
the use of erythrocyte-stimulating agents [3,16,17].
Deferasirox also was well tolerated and was not as-
sociated with any major adverse events. Mild, nonpro-
gressive dose-dependent changes in serum creatinine
concentration have been reported in 30%-40% of
patients with myelodysplastic syndromes and transfu-
sion-dependent anemias treated with deferasirox
[9,10,18]. Our study protocol specifically excluded
patients with renal insufficiency, given the
nephrotoxicity potential of deferasirox. Two of 3
allogeneic HCT recipients in our study experienced
a minor, reversible increase in serum creatinine
concentration during deferasirox therapy. Neither of
these patients was on calcineurin inhibitor therapy.
Calcineurin inhibitors are important and frequently
used immunosuppressive agents for the prevention
and treatment of GVHD after HCT. The safety and
feasibility of using deferasirox concurrently with
calcineurin inhibitors requires further study.
Our observation that serum ferritin concentration
and LIC can decrease without treatment in a subset of
patients is particularly interesting. Excess body iron
may be utilized for posttransplantation hematopoiesis,
Biol Blood Marrow Transplant 16:832-837, 2010 837Iron Overload in HCT Survivorswith a resultant decrease in iron levels over time. The
natural history of iron overload in adult HCT survi-
vors, who receive RBC transfusions transiently around
the treatment of their hematologic malignancy and
HCT and then become transfusion-independent,
merits further investigation.
In conclusion, phlebotomy is feasible in the major-
ity of allogeneic HCT survivors with significant iron
overload. Although only a small number of patients
were studied, our findings suggest that deferasirox
may be a safe and effective alternative for allogeneic
HCT survivors with iron overload who cannot
undergo phlebotomy.ACKNOWLEDGMENTS
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